Franklin Resources
NRIX icon

Franklin Resources’s Nurix Therapeutics NRIX Stock Holding History

Franklin Resources’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,077
Closed -$269K – 3221
2025
Q3 		$269K Sell
29,077
-41,784
-59% -$434K ﹤0.01% 2713
2025
Q2 		$807K Buy
70,861
+9,352
+15% +$101K ﹤0.01% 2095
2025
Q1 		$731K Sell
61,509
-58,936
-49% -$986K ﹤0.01% 2103
2024
Q4 		$2.27M Sell
120,445
-2,656
-2% -$60.9K ﹤0.01% 1687
2024
Q3 		$3.1M Buy
123,101
+42,315
+52% +$959K ﹤0.01% 1566
2024
Q2 		$1.69M Buy
80,786
+16,314
+25% +$254K ﹤0.01% 1750
2024
Q1 		$948K Buy
64,472
+41,851
+185% +$450K ﹤0.01% 1979
2023
Q4 		$233K Sell
22,621
-11
-0% -$75 ﹤0.01% 2291
2023
Q3 		$178K Sell
22,632
-259
-1% -$2.37K ﹤0.01% 2351
2023
Q2 		$229K Buy
+22,891
New +$233K ﹤0.01% 2323

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources's NRIX Position: Q4 2025 in Review

Franklin Resources sold out of Nurix Therapeutics (NRIX) in Q4 2025, closing a stake of 29,077 shares — an estimated $269K sold.

Franklin Resources first reported a position in NRIX in Q2 2023 and held it in 10 quarters. The position peaked at $3.1M in Q3 2024. 182 funds tracked by Wall St. Rank hold NRIX as of Q4 2025.

  • Franklin Resources reported no remaining Nurix Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Franklin Resources sold 29,077 Nurix Therapeutics shares in Q4 2025, an estimated $269K.
  • Franklin Resources first reported a position in Nurix Therapeutics in Q2 2023 and held it in 10 quarters.
  • Franklin Resources's Nurix Therapeutics position peaked at $3.1M in Q3 2024.
  • 182 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2025.

Based on Franklin Resources's 13F filing for Q4 2025, filed 11 Feb 2026.